156 Renal Cell Carcinoma Multimodality Conference: (010322)

Dallas, TX US
January 3, 2022

To improve the care of patients with RCC. This Conference is focused primarily on the discussion of patient cases and periodically of clinical and basic research relevant to RCC

Target Audience

For physicians, PAs, RNs, researchers, medical and graduate students

Learning Objectives

The advancement of diagnosis and treatment of RCC through interdisciplinary expert discussions.  After this conference, participants can explain and utilize  information obtained for enhanced patient care

Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
01/03/2022
Course expires: 
01/03/2022
Event starts: 
01/03/2022 - 5:15pm CST
Event ends: 
01/03/2022 - 6:15pm CST
Cost:
$0.00
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75235
United States

 

 

 

 

 

 

 

Committee member(s)

James Brugarolas, Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor, Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease

has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.

Jeffrey Cadeddu, MD

has a financial relationship (Stock Options) with Monarch Bioimplants;.
has a financial relationship (Stock) with Onconano;.
has a financial relationship (Stock Options) with Levita Magnetics;.

Hans Hammers, MD PhD

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Independent contractor) with Corvus;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Armo Biosciences;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Surface Oncology;.

Raquibul Hannan, MD, PhD, Associate Professor

has no relevant financial relationships to disclose at this time.
Course Director(s)

James Brugarolas, Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor, Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease

has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
Moderator(s)

Waddah Arafat

has no relevant financial relationships to disclose at this time.

Suzanne Cole

has no relevant financial relationships to disclose at this time.

Kevin Courtney, MD, PhD

has a financial relationship (Patent) with Athena Diagnostics;.
has a financial relationship (Stock) with Regeneron Pharmaceuticals Inc;.
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Independent contractor) with Exelixis;.

Jeffrey Howard

has no relevant financial relationships to disclose at this time.

Payal Kapur, MD

has no relevant financial relationships to disclose at this time.

Ivan Pedrosa, M.D., Ph.D.

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Stock Options) with Health Tech International;.

Qian Qin, MD

has no relevant financial relationships to disclose at this time.
Planner(s)

Jeffrey Cadeddu, MD

has a financial relationship (Stock Options) with Levita Magnetics;.
has a financial relationship (Stock Options) with Monarch Bioimplants;.
has a financial relationship (Stock) with Onconano;.
Speaker(s)

Payal Kapur, MD

has no relevant financial relationships to disclose at this time.

Ivan Pedrosa, M.D., Ph.D.

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Stock Options) with Health Tech International;.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.